Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active Myeloma (TACTAM)

Trial Profile

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With Active Myeloma (TACTAM)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Autologous cytotoxic T cell therapeutic Marker Cell Therapeutics (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms TACTAM
  • Most Recent Events

    • 04 Dec 2018 Results assessing Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 27 Nov 2018 According to a Marker Therapeutics Inc media release, results from this study will be presented at the 60th American Society of Hematology Annual Meeting (ASH 2018).
    • 17 Oct 2018 According to a Marker Therapeutics Inc, after the merger of the parent companies (TapImmune and Marker Therapeutics Inc.), the subsidiary, Marker Therapeutics changed its name to Marker Cell Therapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top